Elizabeth Louise Hartland - Infectious Diseases

Author Information

Elizabeth Louise Hartland is a prominent researcher in the field of Infectious Diseases. She is affiliated with the Centre for Innate Immunity and Infectious Diseases at the Hudson Institute of Medical Research, located in Clayton, VIC, Australia. Her work focuses on understanding the molecular mechanisms of bacterial pathogenesis, host-pathogen interactions, and innate immune responses.

Research Contributions

Elizabeth Louise Hartland has made significant contributions to the field of cellular microbiology and infectious diseases. Her research includes the study of virulence factors in pathogens such as Listeria monocytogenes, Escherichia coli, and Legionella pneumophila. Hartland's work on understanding how these pathogens evade host immune responses and manipulate host cell functions is crucial for developing new therapeutic strategies. Notable publications include studies on bacterial clearance mechanisms in macrophages and the role of interferon-induced GTPases in host defense.

Aliases

Throughout her academic career, Elizabeth Louise Hartland has published under various aliases, including E. Hartland, E. L. Hartland, Elizabeth Hartland, Elizabeth L. Hartland, and E L Hartland.

Publication and Citation Metrics

Metric	Value
Total Citations	8570
h-index	51
Total Papers	186

Publications:

Inhibition of the master regulator of Listeria monocytogenes virulence enables bacterial clearance from spacious replication vacuoles in infected macrophages

DOI: 10.1371/journal.ppat.1010166

Year: 2022

Interferon-induced GTPases orchestrate host cell-autonomous defence against bacterial pathogens

DOI: 10.1042/BST20200900

Year: 2021

Issue information

DOI: 10.1002/pro.3886

Year: 2021

Measuring Effector-Mediated Modulation of Inflammatory Responses to Infection with Enteropathogenic and Shiga Toxin-Producing E. coli.

DOI: 10.1007/978-1-0716-1339-9_15

Year: 2021

Emerging methods in cellular microbiology

DOI: 10.1111/cmi.13369

Year: 2021

NleB2 from enteropathogenic Escherichia coli is a novel arginine-glucose transferase effector

DOI: 10.1371/journal.ppat.1009658

Year: 2021

Faculty Opinions recommendation of Shigella ubiquitin ligase IpaH7.8 targets gasdermin D for degradation to prevent pyroptosis and enable infection.

DOI: 10.3410/f.740758534.793589164

Year: 2021

Structural and functional study of Legionella pneumophila effector RavA

DOI: 10.1002/pro.4057

Year: 2021

Genome‐wide genetic screen identifies host ubiquitination as important for Legionella pneumophila Dot/Icm effector translocation

DOI: 10.1111/cmi.13368

Year: 2021

Structural and Functional Characterization of Legionella pneumophila Effector MavL

DOI: 10.3390/biom11121802

Year: 2021

What Are the Preventive Measures?

What are Infectious Agents?

What Kind of Data is Collected?

How Does Chronic Inflammation Affect Infectious Diseases?

Is Fatigue a Long-term Issue in Infectious Diseases?

Are There Concerns About Antiviral Resistance?

How does Aedes Albopictus Spread?

How Does the NIH Support Global Health?

Which Are the Common Bacterial Pathogens?

How can Plasmodium falciparum malaria be prevented?

Partnered Content Networks

Relevant Topics